<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>National Heart and Lung Institute</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/4608E704-6475-4CCA-AD08-F356E4757A3D"><gtr:id>4608E704-6475-4CCA-AD08-F356E4757A3D</gtr:id><gtr:firstName>Tracy</gtr:firstName><gtr:surname>Hussell</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0802752"><gtr:id>5B729222-75BB-4664-BF2F-3C39EA8879F0</gtr:id><gtr:title>Innate immune parameters leading to virus-induced secondary bacterial pneumonia and sepsis.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0802752</gtr:grantReference><gtr:abstractText>Influenza virus causes significant illness and death annually, which drives the development of vaccines for those most at risk. However, it is not widely appreciated that influenza does not always act alone. In combination with bacteria, this viral disease is much worse and the prognosis poor. This is not simply a problem with seasonal influenza virus strains. Recently, researchers have re-analysed specimens taken from those that died during the most severe pandemics and revealed a plethora of bacterial species. In a large proportion multiple bacterial species were present. Why do they cause a problem in some influenza infected individuals and not others? We believe that an individuals past infection history and consequent status of immune cell activity are responsible. We have evidence that influenza alters the activity of key anti-bacterial immune cells in the lower airways rendering them un-responsive to bacteria where they expand and cause pneumonia. We will now dissect this effect to gain a better understanding of the full complexities of this combined infectious disease. Such analysis may identify critical pathways that allow this virus-induced bacterial problem to occur in the first place, which will assist in the identification of those most at risk and potential avenues for targeted treatment. We will also analyse the impact of antibiotics that have different modes of action since it is clear that some strategies result in a worse outcome. The research will provide a possibility for better informed patient management in the future.</gtr:abstractText><gtr:technicalSummary>Secondary bacterial pneumonia is a common occurrence after lung influenza virus infection and leads to a significantly worse prognosis. It is now apparent that 4 to 14 days after resolution of influenza-induced symptoms a recurrence of fever, dyspnea, productive cough, and pulmonary consolidation arises in some due to a bacterial super infection, most commonly caused by Streptococcus pneumoniae, Staphylococcus aureus and Haemophilus influenzae. Bacterial complications are not restricted to seasonal influenza strains. A recent re-analysis of post mortem specimens from past influenza pandemics show a previously unappreciated high frequency of bacterial species in the lower airways that are usually restricted to the nasopharynx. We have recently published two key influences of influenza on the lung that are likely to contribute to bacterial susceptibility: 1) a long term de-sensitisation of alveolar macrophages to subsequent bacterial products and 2) an increase of macrophage innate immune regulatory pathways that reduce their immediate response to bacteria. Using robust viral/bacterial co-infection models in mice we have generated preliminary data showing that a severe outcome correlates with entry of lung bacteria into the blood. Furthermore, we show that systemic spread of bacteria is critically determined by the state of activation of innate immune cells in the airways. Lowering the threshold above which myeloid cells respond to bacteria (by removing a negative regulator) limits bacterial replication in the lung and prevents sepsis and death. We now take this important concept further to ask: 1) how does the balance of immune potentiators and negative regulators influence the bacterial super-infection following influenza? We will develop the system further to examine the critical role of the epithelium in controlling myeloid cell activity and 2) determine which type of antibiotic is beneficial to prevent bacterial complications following influenza, when they should be administered and whether a peripheral inflammatory mediator profile exists that might assist antibiotic choice. These key questions will provide a detailed and mechanistic insight into the clinically important problem of bacterial super-infections that are likely to have direct clinical implications.</gtr:technicalSummary><gtr:fund><gtr:end>2013-11-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>595132</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MCCIR</gtr:description><gtr:id>FC504D02-C6DE-4756-9F45-C327DFE0A045</gtr:id><gtr:impact>The formation of the Manchester Collaborative Centre for Inflammation Research</gtr:impact><gtr:partnerContribution>They provide the funds, access to high throughput screening and tools to enable identification of new pathways relevant to inflammation</gtr:partnerContribution><gtr:piContribution>I have been appointed director of this &amp;pound;15M new initiative and recruited due to my expertise in understanding basic inflammatory processes. THe research generated through MRC funding forms the basis of this new Centre</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>MCCIR</gtr:description><gtr:id>2B702F8A-A841-4917-970D-2E8235110D3E</gtr:id><gtr:impact>The formation of the Manchester Collaborative Centre for Inflammation Research</gtr:impact><gtr:partnerContribution>They provide the funds, access to high throughput screening and tools to enable identification of new pathways relevant to inflammation</gtr:partnerContribution><gtr:piContribution>I have been appointed director of this &amp;pound;15M new initiative and recruited due to my expertise in understanding basic inflammatory processes. THe research generated through MRC funding forms the basis of this new Centre</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Education session for nurses</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>526BBF33-8F5B-47D0-A52A-F95849D9CC3A</gtr:id><gtr:impact>60+ nurses and health professionals attend an acredited update on vaccination for pneumococcal disease. This is held in multiple locations across Britain

This talk is designed to encourage health professionals to vaccinate against Streptotoccus pneumoniae since this causes significant mortality following influenza infection and in multiple other patient groups</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visits</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BD460672-0E79-44D5-AAA9-5AB6EEC2EDDB</gtr:id><gtr:impact>I regularly attend schools to speak with 6th form pupils and I'm on the biology for all website

Many school children have subsequently come to do work in my laboratory</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>68000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MOSAIC consortium</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>090382/Z/09/A</gtr:fundingRef><gtr:id>0E31516A-CBF3-412D-858D-DE1F17F41CFD</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sir Henry Wellcome Fellowship</gtr:description><gtr:end>2011-04-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>17CA28F9-264F-4BA1-AB8A-D0215D0950B4</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>275000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Training Fellowship</gtr:description><gtr:end>2011-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0802353</gtr:fundingRef><gtr:id>F2693446-29A0-4E30-B360-CC00830D99E8</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Centre for Respiratory Infection</gtr:department><gtr:description>Centre for respiratory infection infrastructure award</gtr:description><gtr:end>2010-02-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>95135BFF-1282-4350-B96E-FF7194737A54</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BB99BA91-28C0-4006-A535-F06B551CE473"><gtr:id>BB99BA91-28C0-4006-A535-F06B551CE473</gtr:id><gtr:title>Accumulation of human-adapting mutations during circulation of A(H1N1)pdm09 influenza virus in humans in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/db9a89e402a484ffe65964fd920c99fb"><gtr:id>db9a89e402a484ffe65964fd920c99fb</gtr:id><gtr:otherNames>Elderfield RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/30C91EA4-B2F7-4E6D-A406-8CFF1DE4DA1C"><gtr:id>30C91EA4-B2F7-4E6D-A406-8CFF1DE4DA1C</gtr:id><gtr:title>Immune modulatory strategies: a playground with a swing and a seesaw.</gtr:title><gtr:parentPublicationTitle>Expert review of anti-infective therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/86142b460f1cf0a7ecf7e1718361b611"><gtr:id>86142b460f1cf0a7ecf7e1718361b611</gtr:id><gtr:otherNames>Hussell T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1478-7210</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FCED3B5C-1B90-496A-8B30-48794A2F93F3"><gtr:id>FCED3B5C-1B90-496A-8B30-48794A2F93F3</gtr:id><gtr:title>Respiratory viral infections: knowledge based therapeutics.</gtr:title><gtr:parentPublicationTitle>Current opinion in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/86142b460f1cf0a7ecf7e1718361b611"><gtr:id>86142b460f1cf0a7ecf7e1718361b611</gtr:id><gtr:otherNames>Hussell T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0952-7915</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/15FDB98A-AD0B-4020-9BEC-C112100836E2"><gtr:id>15FDB98A-AD0B-4020-9BEC-C112100836E2</gtr:id><gtr:title>Sedation &amp;amp; immunomodulation.</gtr:title><gtr:parentPublicationTitle>Anesthesiology clinics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f2e5b1ee3098b90568bcaf68ba8fb2f9"><gtr:id>f2e5b1ee3098b90568bcaf68ba8fb2f9</gtr:id><gtr:otherNames>Sanders RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-2275</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EE08AE34-C71E-47BD-A23E-D91F8837CD07"><gtr:id>EE08AE34-C71E-47BD-A23E-D91F8837CD07</gtr:id><gtr:title>Lowering the threshold of lung innate immune cell activation alters susceptibility to secondary bacterial superinfection.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0ad12f521963eb3602f7aeea5be777af"><gtr:id>0ad12f521963eb3602f7aeea5be777af</gtr:id><gtr:otherNames>Goulding J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B62072B1-314F-4AEC-B86D-C9B2DC00F335"><gtr:id>B62072B1-314F-4AEC-B86D-C9B2DC00F335</gtr:id><gtr:title>Altered regulation of Toll-like receptor responses impairs antibacterial immunity in the allergic lung.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/74a843e1bf5df83a3207bc7319d16b1e"><gtr:id>74a843e1bf5df83a3207bc7319d16b1e</gtr:id><gtr:otherNames>Habibzay M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E6ABC841-C0A7-467B-A2B6-C03EAD3A2806"><gtr:id>E6ABC841-C0A7-467B-A2B6-C03EAD3A2806</gtr:id><gtr:title>Bacterial superinfection following lung inflammatory disorders.</gtr:title><gtr:parentPublicationTitle>Future microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/74a843e1bf5df83a3207bc7319d16b1e"><gtr:id>74a843e1bf5df83a3207bc7319d16b1e</gtr:id><gtr:otherNames>Habibzay M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1746-0913</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/09B6A6AC-F83D-4049-A47A-BCF5BF20B61E"><gtr:id>09B6A6AC-F83D-4049-A47A-BCF5BF20B61E</gtr:id><gtr:title>Alveolar macrophages: plasticity in a tissue-specific context.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/86142b460f1cf0a7ecf7e1718361b611"><gtr:id>86142b460f1cf0a7ecf7e1718361b611</gtr:id><gtr:otherNames>Hussell T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F5D3EAF3-68E8-48D7-BEEE-B755B4742DC1"><gtr:id>F5D3EAF3-68E8-48D7-BEEE-B755B4742DC1</gtr:id><gtr:title>Epidemiological isolation causing variable mortality in Island populations during the 1918-1920 influenza pandemic.</gtr:title><gtr:parentPublicationTitle>Influenza and other respiratory viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b28022a9016ea41bb96a369828fb0d54"><gtr:id>b28022a9016ea41bb96a369828fb0d54</gtr:id><gtr:otherNames>Shanks GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1750-2640</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2707D2EB-82EE-4159-BA40-2BC26BB12A23"><gtr:id>2707D2EB-82EE-4159-BA40-2BC26BB12A23</gtr:id><gtr:title>Airway immune homeostasis and implications for influenza-induced inflammation.</gtr:title><gtr:parentPublicationTitle>Trends in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1e89c7491a7c08182477b643557a4377"><gtr:id>1e89c7491a7c08182477b643557a4377</gtr:id><gtr:otherNames>Snelgrove RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1471-4906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B6468B69-4AE7-4A6D-9DBF-FFF0EFC49EC2"><gtr:id>B6468B69-4AE7-4A6D-9DBF-FFF0EFC49EC2</gtr:id><gtr:title>OX40 ligand fusion protein delivered simultaneously with the BCG vaccine provides superior protection against murine Mycobacterium tuberculosis infection.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1e89c7491a7c08182477b643557a4377"><gtr:id>1e89c7491a7c08182477b643557a4377</gtr:id><gtr:otherNames>Snelgrove RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/08B65C05-299D-4ABE-8637-50C57754649E"><gtr:id>08B65C05-299D-4ABE-8637-50C57754649E</gtr:id><gtr:title>An epithelial circadian clock controls pulmonary inflammation and glucocorticoid action.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fbe77509019047feebf5c8d6e8a47b0d"><gtr:id>fbe77509019047feebf5c8d6e8a47b0d</gtr:id><gtr:otherNames>Gibbs J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9133D049-0E58-4BB2-9C5D-306B8B0F8ACF"><gtr:id>9133D049-0E58-4BB2-9C5D-306B8B0F8ACF</gtr:id><gtr:title>The microbiology of asthma.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8603744bac0fd9c512c0c37ca4382a6a"><gtr:id>8603744bac0fd9c512c0c37ca4382a6a</gtr:id><gtr:otherNames>Edwards MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1740-1526</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/949544B6-1FFB-4D73-8DC8-8F41C833E154"><gtr:id>949544B6-1FFB-4D73-8DC8-8F41C833E154</gtr:id><gtr:title>Influenza promotes collagen deposition via av?6 integrin-mediated transforming growth factor ? activation.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9457494eac5e2b9f94aafa962dda9f56"><gtr:id>9457494eac5e2b9f94aafa962dda9f56</gtr:id><gtr:otherNames>Jolly L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8233DE8F-9810-4BB7-A300-9511E8425240"><gtr:id>8233DE8F-9810-4BB7-A300-9511E8425240</gtr:id><gtr:title>IFITM3 restricts the morbidity and mortality associated with influenza.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8080feaaa6a1c8bc11a2811ee3812b4f"><gtr:id>8080feaaa6a1c8bc11a2811ee3812b4f</gtr:id><gtr:otherNames>Everitt AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3F33D35A-9623-4D87-8E43-A28AFF3B2D1A"><gtr:id>3F33D35A-9623-4D87-8E43-A28AFF3B2D1A</gtr:id><gtr:title>Macrophage-mediated inflammation and disease: a focus on the lung.</gtr:title><gtr:parentPublicationTitle>Mediators of inflammation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2dc28afd332af329245e95f98cb94c01"><gtr:id>2dc28afd332af329245e95f98cb94c01</gtr:id><gtr:otherNames>Gwyer Findlay E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0962-9351</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/664A9F5C-3715-4A3D-9815-2909BF741D06"><gtr:id>664A9F5C-3715-4A3D-9815-2909BF741D06</gtr:id><gtr:title>A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1e89c7491a7c08182477b643557a4377"><gtr:id>1e89c7491a7c08182477b643557a4377</gtr:id><gtr:otherNames>Snelgrove RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1BB40E9D-14D1-435C-BDCC-555CD2145D80"><gtr:id>1BB40E9D-14D1-435C-BDCC-555CD2145D80</gtr:id><gtr:title>IL-17 boosts proinflammatory outcome of antiviral response in human cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b1d84a4833493a5f2de6c0e6f9c85b75"><gtr:id>b1d84a4833493a5f2de6c0e6f9c85b75</gtr:id><gtr:otherNames>Ryzhakov G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D9C8657B-2688-4290-BC75-E6E4FF0A535C"><gtr:id>D9C8657B-2688-4290-BC75-E6E4FF0A535C</gtr:id><gtr:title>Airway structural cells regulate TLR5-mediated mucosal adjuvant activity.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d5bfc09885181b70e5c3577b460da9e9"><gtr:id>d5bfc09885181b70e5c3577b460da9e9</gtr:id><gtr:otherNames>Van Maele L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/628687CF-5A6D-4404-9F79-0F929733F781"><gtr:id>628687CF-5A6D-4404-9F79-0F929733F781</gtr:id><gtr:title>Parenteral fluids do not affect pulmonary immune responses to influenza or susceptibility to secondary bacterial pneumonia in mice.</gtr:title><gtr:parentPublicationTitle>Influenza and other respiratory viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f2e5b1ee3098b90568bcaf68ba8fb2f9"><gtr:id>f2e5b1ee3098b90568bcaf68ba8fb2f9</gtr:id><gtr:otherNames>Sanders RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1750-2640</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0F7CBCF6-A172-424C-8B58-2C46D2D5F0C8"><gtr:id>0F7CBCF6-A172-424C-8B58-2C46D2D5F0C8</gtr:id><gtr:title>Structured regulation of inflammation during respiratory viral infection.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/86142b460f1cf0a7ecf7e1718361b611"><gtr:id>86142b460f1cf0a7ecf7e1718361b611</gtr:id><gtr:otherNames>Hussell T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/08335162-D46E-4128-B980-EBF81004CCC7"><gtr:id>08335162-D46E-4128-B980-EBF81004CCC7</gtr:id><gtr:title>OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2dc28afd332af329245e95f98cb94c01"><gtr:id>2dc28afd332af329245e95f98cb94c01</gtr:id><gtr:otherNames>Gwyer Findlay E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/00B44250-4C45-4658-9BF3-A9424E91AE74"><gtr:id>00B44250-4C45-4658-9BF3-A9424E91AE74</gtr:id><gtr:title>Benzodiazepine augmented ?-amino-butyric acid signaling increases mortality from pneumonia in mice.</gtr:title><gtr:parentPublicationTitle>Critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f2e5b1ee3098b90568bcaf68ba8fb2f9"><gtr:id>f2e5b1ee3098b90568bcaf68ba8fb2f9</gtr:id><gtr:otherNames>Sanders RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0090-3493</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802752</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>